BACKGROUND AND PURPOSE: Vascular endothelial growth factor (VEGF) can induce matrix metalloproteinase (MMP)-9 activities and focal angiogenesis. We hypothesized that VEGF activation of cerebral MMP-9 would require nitric oxide participation. METHODS: We compared the in vivo effects of: (1) N(G)-monomethyl-l-arginine, a nonspecific nitric oxide synthase inhibitor; (2) L-N(6)-(1-iminoethyl)lysine, an inducible nitric oxide synthase selective inhibitor; and (3) doxycycline, a known nonspecific inhibitor of MMP in the mouse brain, using in situ zymography and endothelial marker CD31. 3-nitrotyrosine was used as a surrogate for nitric oxide activity. Inflammatory cell markers CD68 and MPO were used to confirm leukocyte infiltration. RESULTS: VEGF-stimulated MMP-9 activity expressed primarily around cerebral microvessels. N(G)-monomethyl-l-arginine suppressed cerebral angiogenesis (P<0.05), especially those microvessels associated with MMP-9 activation (P<0.02) induced by VEGF, comparable to the effect of doxycycline. L-N(6)-(1-iminoethyl)lysine showed similar inhibitory effects. 3-nitrotyrosine confirmed nitric oxide levels in the brain. Compared with the lacZ control, VEGF increased inflammatory cell infiltration, especially macrophages, in the induced brain angiogenic focuses. CONCLUSIONS: Inhibition of nitric oxide production decreased MMP-9 activity and focal angiogenesis in the VEGF-stimulated brain. Both specific and nonspecific inhibition of nitric oxide synthase resulted in similar reductions, suggesting that VEGF-stimulated cerebral MMP activity and angiogenesis are predominantly mediated through inducible nitric oxide synthase, a specific nitric oxide synthase isoform mediating inflammatory responses.
BACKGROUND AND PURPOSE:Vascular endothelial growth factor (VEGF) can induce matrix metalloproteinase (MMP)-9 activities and focal angiogenesis. We hypothesized that VEGF activation of cerebral MMP-9 would require nitric oxide participation. METHODS: We compared the in vivo effects of: (1) N(G)-monomethyl-l-arginine, a nonspecific nitric oxide synthase inhibitor; (2) L-N(6)-(1-iminoethyl)lysine, an inducible nitric oxide synthase selective inhibitor; and (3) doxycycline, a known nonspecific inhibitor of MMP in the mouse brain, using in situ zymography and endothelial marker CD31. 3-nitrotyrosine was used as a surrogate for nitric oxide activity. Inflammatory cell markers CD68 and MPO were used to confirm leukocyte infiltration. RESULTS:VEGF-stimulated MMP-9 activity expressed primarily around cerebral microvessels. N(G)-monomethyl-l-arginine suppressed cerebral angiogenesis (P<0.05), especially those microvessels associated with MMP-9 activation (P<0.02) induced by VEGF, comparable to the effect of doxycycline. L-N(6)-(1-iminoethyl)lysine showed similar inhibitory effects. 3-nitrotyrosine confirmed nitric oxide levels in the brain. Compared with the lacZ control, VEGF increased inflammatory cell infiltration, especially macrophages, in the induced brain angiogenic focuses. CONCLUSIONS: Inhibition of nitric oxide production decreased MMP-9 activity and focal angiogenesis in the VEGF-stimulated brain. Both specific and nonspecific inhibition of nitric oxide synthase resulted in similar reductions, suggesting that VEGF-stimulated cerebral MMP activity and angiogenesis are predominantly mediated through inducible nitric oxide synthase, a specific nitric oxide synthase isoform mediating inflammatory responses.
Authors: Irina Rivilis; Malgorzata Milkiewicz; Pamela Boyd; Jason Goldstein; Margaret D Brown; Stuart Egginton; Fay M Hansen; Olga Hudlicka; Tara L Haas Journal: Am J Physiol Heart Circ Physiol Date: 2002-06-13 Impact factor: 4.733
Authors: Vineet Bhandari; Rayman Choo-Wing; Svetlana P Chapoval; Chun G Lee; C Tang; Y K Kim; Bing Ma; Peter Baluk; Michelle I Lin; Donald M McDonald; Robert J Homer; William C Sessa; Jack A Elias Journal: Proc Natl Acad Sci U S A Date: 2006-07-10 Impact factor: 11.205
Authors: Bing-Qiao Zhao; Sophia Wang; Hahn-Young Kim; Hannah Storrie; Bruce R Rosen; David J Mooney; Xiaoying Wang; Eng H Lo Journal: Nat Med Date: 2006-03-26 Impact factor: 53.440
Authors: Guo-Yuan Yang; Bin Xu; Tomoki Hashimoto; Madeleine Huey; Thomas Chaly; Rong Wen; William L Young Journal: Angiogenesis Date: 2003 Impact factor: 9.596
Authors: Xiaoying Wang; Sun-Ryung Lee; Ken Arai; Seong-Ryong Lee; Kiyoshi Tsuji; G William Rebeck; Eng H Lo Journal: Nat Med Date: 2003-09-07 Impact factor: 53.440
Authors: Zezong Gu; Marcus Kaul; Boxu Yan; Steven J Kridel; Jiankun Cui; Alex Strongin; Jeffrey W Smith; Robert C Liddington; Stuart A Lipton Journal: Science Date: 2002-08-16 Impact factor: 47.728
Authors: J R Connor; P T Manning; S L Settle; W M Moore; G M Jerome; R K Webber; F S Tjoeng; M G Currie Journal: Eur J Pharmacol Date: 1995-01-24 Impact factor: 4.432
Authors: C A Potter; J Armstrong-Wells; H J Fullerton; W L Young; R T Higashida; C F Dowd; V V Halbach; S W Hetts Journal: J Neurointerv Surg Date: 2009-10-23 Impact factor: 5.836
Authors: Nikolaos Mouchtouris; Pascal M Jabbour; Robert M Starke; David M Hasan; Mario Zanaty; Thana Theofanis; Dale Ding; Stavropoula I Tjoumakaris; Aaron S Dumont; George M Ghobrial; David Kung; Robert H Rosenwasser; Nohra Chalouhi Journal: J Cereb Blood Flow Metab Date: 2014-11-19 Impact factor: 6.200
Authors: Alla B Salmina; Yulia K Komleva; István A Szijártó; Yana V Gorina; Olga L Lopatina; Galina E Gertsog; Milos R Filipovic; Maik Gollasch Journal: Front Physiol Date: 2015-12-11 Impact factor: 4.566